CA3102360A1 - Novel anti-pad2 antibody - Google Patents

Novel anti-pad2 antibody Download PDF

Info

Publication number
CA3102360A1
CA3102360A1 CA3102360A CA3102360A CA3102360A1 CA 3102360 A1 CA3102360 A1 CA 3102360A1 CA 3102360 A CA3102360 A CA 3102360A CA 3102360 A CA3102360 A CA 3102360A CA 3102360 A1 CA3102360 A1 CA 3102360A1
Authority
CA
Canada
Prior art keywords
antibody
pad2
amino acid
peptide
positions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3102360A
Other languages
English (en)
French (fr)
Inventor
Kenji Saito
Tomoko SAKATA
Takaaki KAWANOBE
Keita KOGA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma Foods International Co Ltd
Original Assignee
Pharma Foods International Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Foods International Co Ltd filed Critical Pharma Foods International Co Ltd
Publication of CA3102360A1 publication Critical patent/CA3102360A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03006—Arginine deiminase (3.5.3.6)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03015—Protein-arginine deiminase (3.5.3.15)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3102360A 2018-06-20 2019-06-19 Novel anti-pad2 antibody Pending CA3102360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018117142 2018-06-20
JP2018-117142 2018-06-20
PCT/JP2019/024310 WO2019244934A1 (ja) 2018-06-20 2019-06-19 新規抗ｐａｄ２抗体

Publications (1)

Publication Number Publication Date
CA3102360A1 true CA3102360A1 (en) 2019-12-26

Family

ID=68984058

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3102360A Pending CA3102360A1 (en) 2018-06-20 2019-06-19 Novel anti-pad2 antibody

Country Status (6)

Country Link
US (1) US20210246225A1 (enExample)
EP (1) EP3816289A4 (enExample)
JP (2) JP7084057B2 (enExample)
CN (1) CN112262213A (enExample)
CA (1) CA3102360A1 (enExample)
WO (1) WO2019244934A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4501354A1 (en) 2022-03-31 2025-02-05 Pharma Foods International Co., Ltd. Composition and method for inhibiting fibrosis
CN118001407B (zh) * 2024-04-02 2024-06-21 北京大学人民医院 Pad2在制备治疗缺血缺氧性恶性心律失常药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20040110938A1 (en) * 2000-02-24 2004-06-10 Parekh Rajesh Bhikhu Proteins, genes and their use for diagnosis and treatment of schizophrenia
CA2561742A1 (en) * 2004-04-01 2005-10-27 Sequenom, Inc. Methods for identifying risk of osteoarthritis and treatments thereof
WO2007095250A2 (en) * 2006-02-13 2007-08-23 The Cleveland Clinic Foundation Compositions and methods for inhibiting optic nerve damage
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US9718877B2 (en) * 2008-06-04 2017-08-01 Modiquest B.V. Anti-inflammatory agents
US8975033B2 (en) * 2012-11-05 2015-03-10 The Johns Hopkins University Human autoantibodies specific for PAD3 which are cross-reactive with PAD4 and their use in the diagnosis and treatment of rheumatoid arthritis and related diseases
EP2925358A1 (en) * 2012-12-03 2015-10-07 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases
CN104360070B (zh) * 2014-11-28 2017-02-22 山东新创生物科技有限公司 肽基精氨酸脱亚胺酶2在制备肿瘤临床血液诊断试剂中的应用
WO2016155745A1 (en) * 2015-03-27 2016-10-06 Rigshospitalet Cross-reactive anti-pad antibodies

Also Published As

Publication number Publication date
JP7084057B2 (ja) 2022-06-14
US20210246225A1 (en) 2021-08-12
EP3816289A4 (en) 2022-03-02
CN112262213A (zh) 2021-01-22
EP3816289A1 (en) 2021-05-05
WO2019244934A1 (ja) 2019-12-26
JP2022119899A (ja) 2022-08-17
JPWO2019244934A1 (ja) 2021-06-24
JP7411264B2 (ja) 2024-01-11

Similar Documents

Publication Publication Date Title
US12410256B2 (en) Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseases
US12448464B2 (en) Anti-PAD4 antibody
US11697683B2 (en) Anti-IL31 antibodies for veterinary use
JP7624185B2 (ja) 新規抗ｐａｄ４抗体
TWI635097B (zh) 新穎抗人類ｔｓｌｐ受體抗體
AU2013209492B2 (en) Anti-CXCR3 antibodies
AU2021215230B2 (en) Anti-tenascin c antibodies and uses thereof
RU2737145C2 (ru) Антитело, которое обладает способностью нейтрализовать субстанцию, обладающую активностью, альтернативной функции фактора свертывания viii (fviii)
RU2752595C2 (ru) Способ измерения реактивности fviii
CN114555121A (zh) 兽用抗il31抗体
JP7411264B2 (ja) 新規抗ｐａｄ２抗体
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
TWI821804B (zh) Il-7結合蛋白及其於醫療中之用途
JP2023554200A (ja) 抗ＯＸ４０Ｌ抗体、抗ＯＸ４０Ｌ及び抗ＴＮＦαの二重特異性抗体、並びにこれらの用途
TW201139459A (en) Osteopontin-specific monoclonal antibodies

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240605